Home LiteratureArticle Details
PMID: 9343164 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Journal of virology ·Vol. 71 ·No. 11 ·1997-11-00 ·Pages 8141-8

Shibata R, Siemon C, Czajak SC, Desrosiers RC, Martin MA

Abstract

Three rhesus macaques, previously immunized with SIVdelta3 or SIVdelta2, each an attenuated derivative of SIVmac239, and two naive monkeys were challenged with 30,000 50% tissue culture infective doses of SHIV, an SIV/human immunodeficiency virus type 1 (HIV-1) chimeric virus bearing the dual-tropic envelope of HIV-1DH12. By several criteria, including virus isolation, serological assays, and PCR (both DNA and reverse transcriptase), SHIV levels were reduced to barely detectable levels in the circulating blood of vaccinated animals. The resistant SIV-vaccinated macaques had no preexisting neutralizing antibodies directed against SHIV, nor did they produce neutralizing antibodies at any time over a 14-month observation period following SHIV challenge. Interestingly, SIV sequences, derived from the vaccine, could be amplified from numerous tissue samples collected at the conclusion of the experiment, 60 weeks postchallenge, but SHIV-specific sequences (viz., HIV-1 env) could not. These results demonstrate that live attenuated SIV vaccines provide strong long-term protection even against challenge strains with highly divergent envelope sequences.

MeSH Terms
Animals Antibodies, Viral/biosynthesis HIV Antigens/immunology HIV-1/immunology Macaca mulatta Neutralization Tests Reassortant Viruses/immunology Retroviridae Infections/immunology,prevention & control,virology SAIDS Vaccines/immunology Simian Immunodeficiency Virus/immunology Tissue Distribution Vaccines, Attenuated/immunology Viral Proteins/immunology Virus Replication
Chemicals
Antibodies, Viral HIV Antigens SAIDS Vaccines Vaccines, Attenuated Viral Proteins
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Shibata R
Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Siemon C
Czajak S C
Desrosiers R C
Martin M A
References (58)
58 references, click to expand
  1. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.
    J Virol. 1989 Dec;63(12):5046-53 PMID: 2555541
  2. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Nature. 1990 Jun 14;345(6276):622-5 PMID: 2190095
  3. Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV.
    J Virol. 1990 Aug;64(8):3694-700 PMID: 2164591
  4. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.
    Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):542-6 PMID: 1988952
  5. Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees.
    Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3348-52 PMID: 2014254
  6. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells.
    J Virol. 1991 Jul;65(7):3514-20 PMID: 2041078
  7. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences.
    Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7126-30 PMID: 1871125
  8. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.
    Science. 1992 Jan 24;255(5043):456-9 PMID: 1531159
  9. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells.
    Science. 1992 Jun 19;256(5064):1687-90 PMID: 1609280
  10. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection.
    J Virol. 1993 Jan;67(1):577-83 PMID: 8416384
  11. HIV with multiple gene deletions as a live attenuated vaccine for AIDS.
    AIDS Res Hum Retroviruses. 1992 Aug;8(8):1457 PMID: 1466981
  12. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.
    Science. 1992 Dec 18;258(5090):1938-41 PMID: 1470917
  13. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus.
    AIDS Res Hum Retroviruses. 1993 Jan;9(1):13-22 PMID: 8427714
  14. Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells.
    J Med Primatol. 1993 Feb-May;22(2-3):100-3 PMID: 8411101
  15. Immunization of Macaca fascicularis with inactivated SIV preparations: challenge with human- or monkey-derived SIV and the effects of a longer immunization schedule.
    J Med Primatol. 1993 Feb-May;22(2-3):110-8 PMID: 8411103
  16. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines.
    J Virol. 1994 Mar;68(3):1843-53 PMID: 8107246
  17. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine.
    J Acquir Immune Defic Syndr. 1994 Jun;7(6):551-9 PMID: 8176640
  18. Immune responses induced by prototype vaccines for AIDS in rhesus monkeys.
    AIDS Res Hum Retroviruses. 1994 Jan;10(1):27-38 PMID: 8179961
  19. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus.
    AIDS Res Hum Retroviruses. 1994 Feb;10(2):195-204 PMID: 8198872
  20. Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine.
    J Infect Dis. 1994 Jul;170(1):51-9 PMID: 8014520
  21. Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells.
    J Exp Med. 1994 Aug 1;180(2):769-74 PMID: 8046353
  22. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.
    J Virol. 1994 Oct;68(10):6578-88 PMID: 7521918
  23. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge.
    J Virol. 1994 Nov;68(11):7021-9 PMID: 7933084
  24. High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection.
    AIDS Res Hum Retroviruses. 1994 Jul;10(7):839-51 PMID: 7986589
  25. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
    Vaccine. 1994 Sep;12(12):1141-8 PMID: 7998425
  26. Antigenic variation of primate lentiviruses in humans and experimentally infected macaques.
    Immunol Rev. 1994 Aug;140:131-46 PMID: 7821925
  27. Reactivation of human immunodeficiency virus type 2 in macaques after simian immunodeficiency virus SIVmac superinfection.
    J Virol. 1995 Mar;69(3):1564-74 PMID: 7853490
  28. Neither whole inactivated virus immunogen nor passive immunoglobulin transfer protects against SIVagm infection in the African green monkey natural host.
    J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Mar 1;8(3):217-26 PMID: 7532099
  29. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S27-32 PMID: 7865316
  30. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.
    J Virol. 1995 May;69(5):2737-44 PMID: 7707496
  31. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.
    Lancet. 1995 May 27;345(8961):1342-4 PMID: 7752758
  32. Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo.
    J Virol. 1995 Jul;69(7):4453-62 PMID: 7769705
  33. Prior infection with a nonpathogenic chimeric simian-human immunodeficiency virus does not efficiently protect macaques against challenge with simian immunodeficiency virus.
    J Virol. 1995 Jul;69(7):4569-71 PMID: 7769725
  34. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.
    J Virol. 1995 Oct;69(10):6239-48 PMID: 7666524
  35. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques.
    AIDS Res Hum Retroviruses. 1995 Aug;11(8):909-20 PMID: 7492438
  36. Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine.
    Nat Med. 1995 Sep;1(9):914-8 PMID: 7585217
  37. Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge.
    AIDS. 1995 Dec;9(12):F13-8 PMID: 8605046
  38. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.
    J Virol. 1996 Mar;70(3):1953-60 PMID: 8627721
  39. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.
    J Virol. 1996 Jun;70(6):3724-33 PMID: 8648707
  40. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.
    J Virol. 1996 Jun;70(6):3741-52 PMID: 8648709
  41. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.
    Science. 1996 May 24;272(5265):1167-70 PMID: 8638160
  42. Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection.
    J Infect Dis. 1996 Jun;173(6):1327-35 PMID: 8648204
  43. Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. Swiss HIV Cohort Study Group.
    J Infect Dis. 1996 Jun;173(6):1388-93 PMID: 8648210
  44. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1.
    J Virol. 1996 Jul;70(7):4361-9 PMID: 8676459
  45. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques.
    Nat Med. 1996 Jul;2(7):767-75 PMID: 8673922
  46. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study.
    JAMA. 1996 Jul 10;276(2):105-10 PMID: 8656501
  47. Superinfection of HIV-2-preinfected macaques after rectal exposure to a primary isolate of SIVmac251.
    Virology. 1996 Jul 15;221(2):260-70 PMID: 8661436
  48. Fetal or neonatal infection with attenuated simian immunodeficiency virus results in protective immunity against oral challenge with pathogenic SIVmac251.
    Virology. 1996 Aug 1;222(1):275-8 PMID: 8806509
  49. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines.
    Vaccine. 1994 Nov;12(15):1443-52 PMID: 7887023
  50. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus.
    J Gen Virol. 1996 Dec;77 ( Pt 12):2969-81 PMID: 9000087
  51. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239.
    J Virol. 1997 Mar;71(3):1911-21 PMID: 9032322
  52. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing.
    J Infect Dis. 1997 Aug;176(2):362-73 PMID: 9237701
  53. Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope.
    AIDS Res Hum Retroviruses. 1996 Jul 20;12(11):993-9 PMID: 8827215
  54. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.
    J Virol. 1986 Aug;59(2):284-91 PMID: 3016298
  55. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees.
    Nature. 1987 Aug 20-26;328(6132):721-3 PMID: 3475581
  56. Superinfection of a chimpanzee with a second strain of human immunodeficiency virus.
    J Virol. 1987 Dec;61(12):4026-9 PMID: 2446009
  57. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.
    J Virol. 1988 Jan;62(1):139-47 PMID: 3257102
  58. Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac.
    J Virol. 1988 Dec;62(12):4691-6 PMID: 2846880
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/JVI.71.11.8141-8148.1997
Published
1997-11-00
Pages
8141-8
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC192270
Subset
IM
Grants
NIAID NIH HHS · AI35365 · United States
NCRR NIH HHS · RR00168 · United States
External Links
PubMed source DOI: 10.1128/JVI.71.11.8141-8148.1997 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2